Live Breaking News & Updates on Pura Vida Investments Llc

Stay updated with breaking news from Pura vida investments llc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

OncoCyte Co. (NASDAQ:OCX) Sees Large Decrease in Short Interest

OncoCyte Co. (NASDAQ:OCX – Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totalling 1,070,000 shares, a decline of 24.6% from the May 31st total of 1,420,000 shares. Based on an average daily volume of 335,500 shares, the short-interest ratio is presently […] ....

United States , Vanguard Group Inc , Oncocyte Company Profile , Goldman Sachs Group Inc , Oncocyte Corporation , Oncocyte Co , Millennium Management , Defender Capital , Pura Vida Investments Llc , Needham Company , Balyasny Asset Management , Securities Exchange Commission , Free Report , Pura Vida Investments , Exchange Commission , Sachs Group , Asset Management , Cyte Corporation , Oncocyte Daily ,

OncoCyte Co. (NASDAQ:OCX) Sees Significant Decline in Short Interest

OncoCyte Co. (NASDAQ:OCX – Free Report) saw a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 1,070,000 shares, a decline of 24.6% from the May 31st total of 1,420,000 shares. Based on an average daily volume of 335,500 shares, the days-to-cover ratio is currently […] ....

United States , Securities Exchange Commission , Pura Vida Investments Llc , Cubist Systematic Strategies , Oncocyte Co , Oncocyte Corporation , Raymond James Financial Services Advisors Inc , Needham Company , Balyasny Asset Management , Free Report , Pura Vida Investments , Exchange Commission , Systematic Strategies , James Financial Services Advisors , Asset Management , Cyte Corporation , Oncocyte Daily ,

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC decreased their price target on shares of OncoCyte from $1.40 to $0.45 and set a buy rating on the stock […] ....

United States , Oncocyte Company Profile , Raymond James Financial Services Advisors Inc , Oncocyte Corporation , Needham Company , Pura Vida Investments Llc , Vanguard Group Inc , Goldman Sachs Group Inc , Free Report , Pura Vida Investments , James Financial Services Advisors , Sachs Group , Cyte Corporation , Oncocyte Daily ,

StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

Equities researchers at StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report issued on Saturday. The brokerage set a “sell” rating on the stock. Separately, Needham & Company LLC dropped their target price on shares of OncoCyte from $1.40 to $0.45 and set a “buy” rating on the stock in […] ....

United States , Raymond James Financial Services Advisors Inc , Pura Vida Investments Llc , Cubist Systematic Strategies , Needham Company , Oncocyte Corporation , Goldman Sachs Group Inc , Securities Exchange Commission , Free Report , Pura Vida Investments , Exchange Commission , James Financial Services Advisors , Sachs Group , Systematic Strategies , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Friday morning. The firm issued a sell rating on the stock. Separately, Needham & Company LLC decreased their target price on shares of OncoCyte from $1.40 to $0.45 and set a buy rating for the company in a research […] ....

United States , Pura Vida Investments Llc , Goldman Sachs Group Inc , Oncocyte Company Profile , Needham Company , Cubist Systematic Strategies , Oncocyte Corporation , Raymond James Financial Services Advisors Inc , Free Report , Pura Vida Investments , James Financial Services Advisors , Sachs Group , Systematic Strategies , Cyte Corporation , Oncocyte Daily ,